Abstract: The present invention relates to compounds of the general formula (I), ##STR1## in which the radicals have the meaning given in the description, to processes for their preparation and to their use as medicaments.

Abstract: The invention relates to nucleic acid-binding oligomers possessing C-branching of the general formula (I) ##STR1## and to the corresponding monomers, whose radicals have the meaning given in the description, and to their use as medicaments or diagnostic aids.

Abstract: The invention relates to nucleic acid-binding oligomers possessing N-branching of the general formula (I), ##STR1## and their monomers, where the individual radicals have the meaning given in the description, and to their use as medicaments or as aids in diagnostics.

Abstract: The anthracene-spiro-pyrrolidines according to the invention are prepared by reacting either anthracene-spiro-furans or unsubstituted anthracene-spiropyrrolidines with appropriately substituted amines or by reacting unsubstituted anthracene derivatives with appropriately substituted methylenepyrrolidines. The substances can be used as active agents in medicaments, in particular for the production of immunomodulating medicaments.

Abstract: N,N-Disubstitued piperazines are prepared by reacting either the appropriately substituted furans or the N-unsubstituted pyrrolidines with aminoalkylpiperazines. The substances according to the invention can be employed as active agents in medicaments, in particular for the production of immunomodulators.

Abstract: Substituted pyrroloanthracenes are prepared by reacting either furanoanthracenes or N-unsubstituted pyrroloanthracenes with appropriately substituted alkylamines. The compounds can be employed as active ingredients in medicaments, in particular as immunomodulators.

Abstract: The piperazine-substituted pyrroloanthracenes are prepared by reacting either furanoanthracenes with piperazinalkylamines or reacting unsubstituted pyrroloanthracenes first with dihalogenoalkyl compounds and then with appropriately substituted piperazines or by reacting furan derivatives first with piperazinalkylamines and then condensing with anthracenes. The new compounds can be employed as active ingredients in medicaments, in particular in immunomodulators.

Abstract: Circulation active compounds of the formula ##STR1## in which R.sup.1 is phenyl or heterocyclyl substituted by nitro, trifluoromethyl or other radicals,R.sup.2 is optionally substituted alkyl or other radicalR.sup.3 and R.sup.5 are hydrogen, methyl or other radicals,R.sup.4 is hydrogen or optionally substituted alkyl,X is from 2 to 15, andR.sup.6 is ##STR2## and physiologically acceptable salts thereof.

Abstract: Hypertension and cardiac insufficiency can be controlled by 4-nitrophenyl-dihydropyridine amides of the formula ##STR1## in which X can be ethylene or the like,Y is pyridyl or --NR.sup.9 R.sup.10, andR.sup.9 and R.sup.10 each independently is hydrogenor an organic group, or together form a ring, and physiologically tolerated salts thereof. Compounds in which R.sup.5 and R.sup.6 are not aryl or aralkyl are new.

Abstract: Circulation active dihydropyridine amides of the formula ##STR1## in which R.sup.6 represents a group of the formula --O--(CH.sub.2).sub.n --R.sup.10, --S--(CH.sub.2).sub.n --R.sup.10 --O--SO.sub.2 --(CH.sub.2).sub.n R.sup.10 or --O--CO--(CH.sub.2).sub.n --R.sup.10in whichn denotes 0 to 4,andR.sup.10 denotes cyclohexyl, aryl or a heterocyclic ring,and physiologically acceptable salts thereof.

Abstract: Circulation active compounds of the formula ##STR1## in which R.sup.1 is phenyl or heterocyclyl substituted by nitro, trifluoromethyl or other radicals,R.sup.2 is optionally substituted alkyl or other radicalR.sup.3 and R.sup.5 are hydrogen, methyl or other radicals,R.sup.4 is hydrogen or optionally substituted alkyl,X is from 2 to 15, andR.sup.6 is ##STR2## and physiologically acceptable salts thereof.

Abstract: Novel circulation-active cyclohexenecarboxylates of the formula ##STR1## in which R.sup.1 is an organic radical,R.sup.2 is an optionally substituted aryl radical,R.sup.3 is an optionally substituted alkyl or aryl radical,X and Y are --CN, --COR.sup.4, --SO.sub.2 R.sup.4, --COOR.sup.5, --CONR.sup.6 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7, andR.sup.4, R.sup.5, R.sup.6 and R.sup.7 are various organic radicals.

Abstract: Circulation active tetrahydropyridines of the formula ##STR1## in which R.sup.1 represents a straight-chain, branched or cyclic, saturated or unsaturated hydrocarbon radical which has up to 20 carbon atoms and can be interrupted in the chain by an oxygen atom or a sulphur atom and/or can be substituted by halogen, cyano, hydroxyl, acyloxy, nitro or nitrooxy, or by a phenyl, phenoxy, phenylthio or phenylsulphonyl group which is optionally substituted by halogen, cyano, dialkylamino with in each case 1 or 2 carbon atoms per alkyl group, alkoxy with 1 to 4 carbon atoms, alkyl with 1 to 4 carbon atoms, trifluoromethyl or nitro, or by an .alpha.-, .beta.- or .gamma.

Abstract: Circulation active compounds of the formula ##STR1## in which R.sup.1 is phenyl or heterocyclyl substituted by nitro, trifluoromethyl or other radicals,R.sup.2 is optionally substituted alkyl or other radicalR.sup.3 and R.sup.5 are hydrogen, methyl or other radicals,R.sup.4 is hydrogen or optionally substituted alkyl,X is from 2 to 15, andR.sup.6 is ##STR2## and physiologically acceptable salts thereof.

Abstract: Circulation active, e.g. antihypertensive novel methionine-substituted dihydropyridines of the formula ##STR1## in which R.sup.1 is phenyl or a heterocyclic radical, or a physiologically acceptable salt thereof.